Overview

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Status:
Not yet recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
Phase:
Phase 2
Details
Lead Sponsor:
Aristea Therapeutics, Inc.